ストックスクリーナーアプリを入手
13.63
2.10%
0.28
アフターアワーズ：
13.63
前日終値:
$13.35
開ける：
$13.52
24時間の取引高:
399.32K
Relative Volume:
0.98
時価総額：
$733.21M
収益：
$2.22M
当期純損益:
$-40.51M
株価収益率:
-10.61
EPS:
-1.2847
ネットキャッシュフロー:
$-46.53M
1週間 パフォーマンス:
+27.15%
1か月 パフォーマンス:
+25.16%
6か月 パフォーマンス:
+31.18%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$12.74
$13.96
1週間の範囲:
$10.54
$13.96
52週間の値動き範囲:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
UPB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
13.63 | 620.24M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-05 | 開始されました | JP Morgan | Overweight |
| 2024-11-05 | 開始されました | Piper Sandler | Overweight |
| 2024-11-05 | 開始されました | TD Cowen | Buy |
| 2024-11-05 | 開始されました | William Blair | Outperform |
Upstream Bio Inc (UPB) 最新ニュース
What drives Upstream Bio Inc. stock priceOutstanding trading profits - jammulinksnews.com
Upstream Bio Inc. Stock Analysis and ForecastFree Stock Selection - jammulinksnews.com
What analysts say about Upstream Bio Inc. stockOutstanding capital returns - jammulinksnews.com
Is Upstream Bio Inc. a good long term investmentConsistent high-yield stocks - jammulinksnews.com
J.P. Morgan Maintains UpStream Bio(UPB.US) With Buy Rating - 富途牛牛
how upstream bio inc. stock performs during market volatilityFree Stock Market Insider Analysis - Newser
Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share. - AInvest
What risks could impact Upstream Bio Inc. stock performanceHigh Potential Shares - Newser
Why Upstream Bio Inc. stock attracts strong analyst attentionHigh Return Conservative Stocks - Newser
How Upstream Bio Inc. stock performs during market volatilityFast Gains With Reduced Risk - Newser
Upstream Bio management to meet with Piper Sandler - TipRanks
What makes Upstream Bio Inc. stock price move sharplyFree VIP Investment Strategies - Newser
Will Q3 Shape Up To Be A VIBRANT Quarter For Upstream Bio? - RTTNews
Upstream Bio doses first patient in Phase 2 trial of verekitug in COPD - TipRanks
Upstream Bio, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease - MarketScreener
Upstream Bio announces first patient dosed in phase 2 clinical trial of Verekitug - MarketScreener
Upstream Bio begins phase 2 COPD trial for verekitug - Investing.com
Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio - Nasdaq
Upstream Bio Announces First Patient Dosed in Phase 2 - GlobeNewswire
Breakthrough COPD Drug Trial Launches with Unique 24-Week Dosing Schedule, Targeting 670 Patients - Stock Titan
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from Russell 3000 Growth Index - MarketScreener
Rhumbline Advisers Has $82,000 Stock Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Plunges 11.54% Amid Clinical Trial Data Anticipation - AInvest
Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space - TipRanks
Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency - Asianet Newsable
Upstream Bio announces presentation of data on verekitug’s TSLP receptor - TipRanks
Translational Data Illustrate a Mechanism of Greater - GlobeNewswire
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - The Manila Times
Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress - Nasdaq
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewswire Inc.
Bank of America Corp DE Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Holds 2025 Annual Stockholders Meeting - TipRanks
Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen - Defense World
Nuveen Asset Management LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025 - Nasdaq
Upstream Bio to Present Mechanistic Insights into - GlobeNewswire
Breakthrough: Upstream Bio's Verekitug Demonstrates Enhanced Potency Over Current Asthma Treatments - Stock Titan
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Upstream Bio to Reveal Latest Inflammatory Disease Treatment Progress at Major Goldman Sachs Conference - Stock Titan
Upstream Bio Inc (UPB) 財務データ
収益
当期純利益
現金流量
EPS
Upstream Bio Inc (UPB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):